A critical review of therapeutic interventions in sickle cell disease: Progress and challenges
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Chandu Ala und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science Pilani, Medicinal Chemistry Research Laboratory, Pilani Campus, Pilani, Rajasthan, …. Hauptthemen laut MEDLINE: Anemia, Sickle Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSIR (SRF-DIRECT).
Abstract (Originalsprache)
Sickle cell disease (SCD) is an autosomal recessive genetic disorder that occurs due to the point mutation in the β‐globin gene, which results in the formation of sickle hemoglobin (HbS) in the red blood cells (RBCs). When HbS is exposed to an oxygen‐depleted environment, it polymerizes, resulting in hemolysis, vaso‐occlusion pain, and impaired blood flow. Still, there is no affordable cure for this inherited disease. Approved medications held promise but were met with challenges due to limited patient tolerance and undesired side effects, thereby inhibiting their ability to enhance the quality of life across various individuals with SCD. Progress has been made in understanding the pathophysiology of SCD during the past few decades, leading to the discovery of novel targets and therapies. However, there is a compelling need for research to discover medications with improved efficacy and reduced side effects. Also, more clinical investigations on various drug combinations with different mechanisms of action are needed. This review comprehensively presents therapeutic approaches for SCD, including those currently available or under investigation. It covers fundamental aspects of the disease, such as epidemiology and pathophysiology, and provides detailed discussions on various disease‐modifying agents. Additionally, expert insights are offered on the future development of pharmacotherapy for SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science Pilani, Medicinal Chemistry Research Laboratory, Pilani Campus, Pilani, Rajasthan, India.
- CSIR-Institute of Genomics and Integrative Biology, New Delhi, India.
- Department of Chemistry, Birla Institute of Technology and Science, Pilani, Hyderabad Campus, Hyderabad, Telangana, India.
Förderung
- CSIR (SRF-DIRECT)
Zitieren
APA
Ala, C., Joshi, R. P., Gupta, P., Goswami, S. G., Ramalingam, S., Kondapalli Venkata Gowri, C. S., & Sankaranarayanan, M. (2024). A critical review of therapeutic interventions in sickle cell disease: Progress and challenges. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400381
Vancouver
Ala C, Joshi RP, Gupta P, Goswami SG, Ramalingam S, Kondapalli Venkata Gowri CS, et al. A critical review of therapeutic interventions in sickle cell disease: Progress and challenges. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400381
BibTeX
@article{Ala2024,
author = {Ala, Chandu and Joshi, Renuka Parshuram and Gupta, Pragya and Goswami, Sangam Giri and Ramalingam, Sivaprakash and Kondapalli Venkata Gowri, Chandra Sekhar and Sankaranarayanan, Murugesan},
title = {A critical review of therapeutic interventions in sickle cell disease: Progress and challenges},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400381}
}
EUVIMED